AP NEWS

Pharmacovigilance Aspects of Licensing Agreements Programme (London, United Kingdom - October 2nd, 2018) - ResearchAndMarkets.com

September 3, 2018

DUBLIN--(BUSINESS WIRE)--Sep 3, 2018--The “Pharmacovigilance Aspects of Licensing Agreements” conference has been added to ResearchAndMarkets.com’s offering.

This programme will be of interest to all personnel involved in business development and licensing agreements aspects of pharmacovigilance.

Whilst licensing agreements involving medicines are primarily driven by commercial considerations, the successful handling of pharmacovigilance obligations is a critical, but frequently overlooked, consideration. Negotiating the safety arrangements to ensure regulatory compliance by both partners can be a complex process. This is further compounded by lack of harmonisation and clarity of the regulations around the world.

This seminar will review the existing global requirements relating to pharmacovigilance in contractual agreements. The emphasis will be on practical advice as to how to remain compliant with the legal obligations, how to satisfy good pharmacovigilance practice

and quality management requirements, as well as how to promote harmonious business partnerships.

This programme will be of interest to all personnel involved in business development and licensing agreements, including those working in drug safety and pharmacovigilance, regulatory affairs and drug registration, medical directors, R&D directors and company lawyers.

Agenda:

Global regulatory framework

EU, USA and what ICH says How it impacts partnerships What the regulators expect from the pharmacovigilance systemfrom the MAHfrom the MAH’s partners

Best pharmacovigilance practices in licensing agreements

Types of agreement Safety Data Exchange Who is responsible for what Joint handling of pharmacovigilance issues

Legal aspects

The legal status and role of pharmacovigilance agreements Drafting pharmacovigilance agreements contract basics, dos and don’tsterminology, form and contentusing templates Contractual liability and indemnities Amendment and termination of pharmacovigilance agreements

Audit and compliance aspects of third-party agreements

Regulatory expectations and inspections Which agreements to examine at audit What to look for in safety data exchange agreements at pharmacovigilance audit Which partners to audit and how Measuring partner/other party compliance

Workshop session - Practical aspects of licensing agreements

For more information about this conference, visit https://www.researchandmarkets.com/research/pzv4lm/pharmacovigilance?w=4.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180903005325/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/03/2018 04:28 PM/DISC: 09/03/2018 04:28 PM

http://www.businesswire.com/news/home/20180903005325/en

AP RADIO
Update hourly